Autolus Therapeutics to host virtual event to discuss the company’s obe-cel program in systemic lupus erythematosus
- Autolus Therapeutics will hold a virtual event on October 24, 2023 to discuss their CAR T strategy in autoimmune diseases. They will also discuss their decision to advance obecabtagene autoleucel into a Phase 1 study for systemic lupus erythematosus (SLE) in early 2024.
- None.
LONDON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will hold a virtual event on Tuesday, October 24, 2023 at 8:30 am ET, 1:30 pm BST, to discuss the company’s CAR T strategy in autoimmune diseases and recent decision to advance obecabtagene autoleucel (obe-cel) into a Phase 1 study in systemic lupus erythematosus (SLE) in early 2024.
The event will include an introduction from Autolus’s Chief Executive Officer, Dr Christian Itin, and presentations from key thought leader, Dr Maria Leandro, consultant rheumatologist at UCL Hospitals and senior lecturer at University College London, and company management.
Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conference call. A simultaneous audio webcast and replay along with presentation materials will be accessible on the events section of Autolus’s website.
Contact:
Julia Wilson
+44 (0) 7818 430877
j.wilson@autolus.com
Susan A. Noonan
S.A. Noonan Communications
+1-917-513-5303
susan@sanoonan.com
Lauren Williams
Investase
+44 23 9438 7760
lauren@investase.com
FAQ
When is Autolus Therapeutics holding the virtual event?
What will be discussed during the event?
Who will be speaking at the event?
How can participants access the conference call?
Where can the audio webcast and presentation materials be accessed?
